An even larger market for NVS/IDIX to go after aggressively is premenopausal women. Since mother-to-child transmission is one of the main ways people end up with chronic HBV, it’s especially important for women of childbearing age to be treated for HBV early enough to have a decent chance for seroconversion before becoming pregnant.
The HBV sales reps from NVS and IDIX should be telling docs that Tyzeka is the right first-line choice for all premenopausal women. Even those on birth control (because you don’t want someone to be forced to change drugs if she decides to become pregnant after all).
Market Data 
Markets 
AI
